Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLAC vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Treatment of hepatic encephalopathy (portal-systemic encephalopathy) in patients with acute and chronic liver disease,Constipation (including chronic idiopathic constipation)
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Not absorbed systemically. Metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Negligible (<1%); not significantly bound to plasma proteins.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Approximately 0.2 L/kg; indicates distribution primarily in extracellular fluid.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Oral: <2% systemic bioavailability due to extensive first-pass metabolism and local gut action; rectal: minimal systemic absorption.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No dose adjustment required for renal impairment.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor serum electrolytes.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Infants: 2.5-10 m L/day in divided doses. Children: 40-90 mg/kg/day (as lactulose) divided 1-2 times daily, titrated to produce soft stools. For hepatic encephalopathy: 2.5-10 m L (1.7-6.7 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Initiate at lower end of dosing range (15 m L once daily) and titrate slowly to avoid diarrhea and electrolyte imbalance; monitor renal function and electrolytes.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
No FDA black box warning.
Not available.
Electrolyte disturbances (e.g., hypernatremia) may occur, especially with prolonged use or in patients with renal impairment,Diarrhea can lead to fluid and electrolyte loss; dosage should be adjusted to produce 2-3 soft stools per day,Galactose content: lactulose contains galactose and lactose; use with caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption,Risk of colonic perforation in patients with severe colonic ulceration, toxic megacolon, or gastrointestinal obstruction
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Patients with galactosemia (due to galactose content),Gastrointestinal obstruction (including ileus),Hypersensitivity to lactulose or any component of the formulation
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No specific food restrictions. Mixing with fruit juice, water, or milk may improve taste. Avoid excessive intake of dairy products if lactose intolerant (lactulose may contain small amounts of lactose).
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal harm in any trimester.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Excretion into breast milk is negligible due to minimal systemic absorption. M/P ratio not determined. Considered compatible with breastfeeding.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No dose adjustment required during pregnancy; pharmacokinetics unchanged due to localized GI action.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
Cholac (lactulose) is used for constipation and hepatic encephalopathy. Monitor for diarrhea and electrolyte imbalances. In hepatic encephalopathy, titrate dose to achieve 2-3 soft stools per day. Syrup can be mixed with fruit juice or water to improve palatability. Onset of action is 24-48 hours for constipation; for encephalopathy, effects may take several days.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Take exactly as prescribed. Do not change dose without consulting your doctor.,For constipation, effects may take up to 48 hours. Do not use other laxatives unless advised.,For liver disease, it helps reduce ammonia levels. Aim for 2-3 soft bowel movements daily.,May cause gas, bloating, or stomach cramps, which usually decrease over time.,Contact doctor if you have severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and direct light.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLAC vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
CHOLAC is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLAC and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLAC is: 15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLAC and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLAC is classified as Category C. Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal . ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.